Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Autolus Therapeutics Ltd
AUTLCurrent price
2.21 USD
-0.1 USD (-4.33%)
Last closed
2.30 USD
Company
www.autolus.com
ISIN
US05280R1005
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
686 594 752 USD
Yield for 12 month
-69.35 %
1Y
3Y
5Y
10Y
15Y
AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom. Address: The Mediaworks, London, United Kingdom, W12 7FP
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
10.45 USDP/E ratio
–Dividend Yield
–Current Year
+1 698 000 USD
Last Year
+6 194 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-4 867 000 USD
Last Year
-131 026 000 USD
Current Quarter
-223 000 USD
Last Quarter
-1 895 000 USD
Key Figures AUTL
1 year
3 years
5 years
10 years
EBITDA
-205 863 008 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-21.61 %
PEG Ratio
–
Return On Equity TTM
-82.20 %
Wall Street Target Price
10.45 USD
Revenue TTM
10 091 000 USD
Book Value
1.79 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
681.00 %
Dividend Yield
–
Gross Profit TTM
-130 860 000 USD
Earnings per share
-1.22 USD
Diluted Eps TTM
-1.22 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics AUTL
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History AUTL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation AUTL
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
8.10
Price Sales TTM
68.04
Enterprise Value EBITDA
0.033
Price Book MRQ
1.44
Financials AUTL
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators AUTL
For 52 weeks
2.44 USD
7.45 USD
50 Day MA
3.59 USD
Shares Short Prior Month
6 248 827
200 Day MA
4.18 USD
Short Ratio
2.48
Shares Short
6 293 312
Short Percent
3.19 %
BeatStart